Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
Wuhan Hiteck Biological Pharma Co Ltd banner

Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683

Watchlist Manager
Wuhan Hiteck Biological Pharma Co Ltd Logo
Wuhan Hiteck Biological Pharma Co Ltd
SZSE:300683
Watchlist
Price: 31.96 CNY -2.29% Market Closed
Market Cap: ¥4.2B
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

Revenue
+
3Y
-19%
5Y
+24%
10Y
-
Operating Income
+
3Y
-
5Y
-378%
10Y
-
Net Income
+
3Y
-
5Y
-1 111%
10Y
-

Earnings Waterfall
Wuhan Hiteck Biological Pharma Co Ltd

Income Statement
Wuhan Hiteck Biological Pharma Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024 Sep-2024 Dec-2024 Mar-2025 Jun-2025 Sep-2025
Revenue
Interest Expense
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
2
2
3
3
3
2
2
0
0
Revenue
750
N/A
493
-34%
630
+28%
585
-7%
591
+1%
615
+4%
641
+4%
649
+1%
620
-4%
529
-15%
494
-7%
498
+1%
524
+5%
617
+18%
557
-10%
568
+2%
615
+8%
623
+1%
776
+25%
769
-1%
689
-10%
661
-4%
588
-11%
580
-1%
602
+4%
596
-1%
600
+1%
615
+2%
649
+6%
674
+4%
639
-5%
620
-3%
Gross Profit
Cost of Revenue
(35)
(27)
(36)
(37)
(44)
(60)
(73)
(99)
(120)
(119)
(159)
(184)
(215)
(278)
(215)
(220)
(265)
(278)
(402)
(420)
(359)
(355)
(321)
(319)
(370)
(352)
(341)
(354)
(381)
(386)
(388)
(378)
Gross Profit
715
N/A
466
-35%
594
+27%
549
-8%
547
0%
555
+2%
568
+2%
551
-3%
500
-9%
409
-18%
335
-18%
314
-6%
309
-2%
339
+10%
343
+1%
348
+1%
350
+1%
345
-1%
374
+8%
349
-7%
330
-6%
306
-7%
267
-13%
261
-2%
233
-11%
243
+5%
260
+7%
261
+1%
268
+3%
288
+7%
252
-13%
242
-4%
Operating Income
Operating Expenses
(548)
(376)
(488)
(466)
(429)
(474)
(482)
(482)
(446)
(408)
(371)
(361)
(339)
(397)
(402)
(390)
(355)
(355)
(351)
(345)
(358)
(360)
(360)
(368)
(360)
(433)
(431)
(432)
(365)
(368)
(370)
(466)
Selling, General & Administrative
(521)
(336)
(423)
(406)
(399)
(398)
(422)
(424)
(380)
(357)
(306)
(292)
(249)
(287)
(286)
(263)
(250)
(239)
(229)
(225)
(227)
(223)
(233)
(230)
(223)
(266)
(255)
(268)
(245)
(235)
(251)
(257)
Research & Development
(25)
0
0
(10)
(28)
(32)
(48)
(53)
(58)
(62)
(71)
(75)
(78)
(95)
(94)
(105)
(90)
(113)
(118)
(116)
(107)
(116)
(115)
(127)
(117)
(133)
(137)
(127)
(113)
(121)
(109)
(99)
Depreciation & Amortization
(1)
0
0
0
(6)
0
0
0
(12)
0
0
0
(17)
0
0
0
(22)
0
0
0
(30)
0
0
0
(32)
0
0
0
(27)
0
0
0
Other Operating Expenses
(0)
(40)
(65)
(50)
4
(44)
(12)
(4)
4
11
6
6
5
(15)
(22)
(22)
8
(3)
(4)
(4)
5
(21)
(12)
(12)
12
(34)
(40)
(37)
19
(13)
(10)
(110)
Operating Income
168
N/A
90
-46%
106
+18%
83
-22%
118
+43%
81
-32%
86
+6%
69
-20%
54
-21%
1
-97%
(36)
N/A
(47)
-31%
(30)
+36%
(59)
-96%
(59)
-1%
(42)
+29%
(6)
+87%
(10)
-79%
23
N/A
4
-83%
(28)
N/A
(54)
-88%
(93)
-74%
(107)
-14%
(128)
-20%
(189)
-48%
(172)
+9%
(171)
+0%
(97)
+43%
(81)
+17%
(119)
-47%
(224)
-88%
Pre-Tax Income
Interest Income Expense
16
14
24
35
32
33
39
35
39
42
35
29
29
38
29
29
17
19
24
26
22
34
37
38
25
25
23
20
22
18
29
30
Non-Reccuring Items
(18)
0
0
0
(45)
0
0
0
(18)
0
0
0
(35)
(0)
(0)
(0)
10
0
(0)
0
(0)
(0)
0
(3)
(43)
(0)
(0)
2
(1)
0
(0)
(1)
Gain/Loss on Disposition of Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
0
8
9
8
0
(1)
(2)
(3)
(2)
(1)
(1)
(0)
(1)
(2)
(3)
(2)
(1)
2
(1)
(1)
(1)
(4)
(3)
(7)
(7)
(9)
(8)
(5)
(3)
(5)
(5)
(5)
Pre-Tax Income
166
N/A
113
-32%
139
+23%
126
-9%
105
-17%
112
+7%
122
+8%
101
-17%
73
-28%
42
-43%
(1)
N/A
(18)
-1 911%
(37)
-107%
(23)
+38%
(33)
-43%
(16)
+52%
20
N/A
11
-46%
46
+315%
29
-36%
(8)
N/A
(23)
-196%
(59)
-154%
(78)
-33%
(152)
-94%
(174)
-14%
(157)
+10%
(154)
+2%
(80)
+48%
(68)
+16%
(95)
-41%
(200)
-111%
Net Income
Tax Provision
(25)
(17)
(21)
(18)
(14)
(15)
(21)
(17)
(11)
(6)
3
1
12
8
18
20
10
15
4
6
(0)
3
13
16
24
30
17
14
6
(3)
5
8
Income from Continuing Operations
141
95
118
108
92
98
101
84
61
36
2
(17)
(26)
(16)
(15)
5
30
26
49
36
(8)
(20)
(46)
(62)
(128)
(144)
(140)
(141)
(74)
(71)
(90)
(192)
Income to Minority Interest
1
1
2
2
3
3
3
3
2
2
1
1
1
1
1
(0)
(2)
(5)
(10)
(8)
(6)
(3)
2
3
7
8
7
7
4
4
4
5
Net Income (Common)
142
N/A
97
-32%
119
+24%
110
-8%
94
-14%
100
+7%
104
+3%
86
-17%
63
-27%
38
-40%
4
-91%
(16)
N/A
(25)
-61%
(15)
+41%
(14)
+5%
4
N/A
28
+573%
21
-25%
39
+89%
28
-29%
(14)
N/A
(23)
-65%
(44)
-90%
(59)
-35%
(121)
-104%
(136)
-12%
(132)
+3%
(134)
-1%
(69)
+48%
(67)
+4%
(86)
-29%
(188)
-119%
EPS (Diluted)
1.65
N/A
0.93
-44%
1.15
+24%
1.07
-7%
0.91
-15%
0.98
+8%
1.01
+3%
0.84
-17%
0.61
-27%
0.36
-41%
0.03
-92%
-0.16
N/A
-0.24
-50%
-0.15
+38%
-0.14
+7%
0.04
N/A
0.26
+550%
0.18
-31%
0.32
+78%
0.23
-28%
-0.11
N/A
-0.31
-182%
-0.23
+26%
-0.51
-122%
-0.93
-82%
-1.03
-11%
-1.01
+2%
-1.02
-1%
-0.53
+48%
-0.51
+4%
-0.66
-29%
-1.43
-117%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 319,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.